Pseudoxanthoma Elasticum (PXE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Pseudoxanthoma elasticum (PXE) is an inherited metabolic disorder due to ABCC6 gene mutations. It is characterized by progressive calcification and fragmentation of elastic fibers in the skin, retina, and arterial wall. Despite calcium accumulation in the arteries of PXE patients, functional consequences remain unknown.
- According to the literature review conducted by Thelansis, the prevalence of PXE, estimated to be 1 in 50,000, would imply that there are ~8,000–10,000 PXE patients in the United States. With the same global prevalence, there could be as many as 160,000 to 200,000 patients affected with PXE worldwide.
Thelansis’s “Pseudoxanthoma Elasticum (PXE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pseudoxanthoma Elasticum (PXE) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Pseudoxanthoma Elasticum (PXE) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Pseudoxanthoma Elasticum (PXE) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment